Englander Institute for Precision Medicine
Found 797 results
Author Title Type [ Year(Asc)]
Filters: Corrigendum-whole-genome-and-transcriptome-analysis-pancreatic-acinar-cell-carcinoma is   [Clear All Filters]
2020
Hadi K, Yao X, Behr JM, Deshpande A, Xanthopoulakis C, Tian H, Kudman S, Rosiene J, Darmofal M, DeRose J et al..  2020.  Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs.. Cell. 183(1):197-210.e32.
Rescigno P, Dolling D, Conteduca V, Rediti M, Bianchini D, Lolli C, Ong M, Li H, Omlin AG, Schmid S et al..  2020.  Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis.. Eur Urol Oncol. 3(2):176-182.
Vlachostergios PJ, Faltas BM, Carlo MI, Nassar AH, Alaiwi SAbou, Sonpavde G.  2020.  The emerging landscape of germline variants in urothelial carcinoma: Implications for genetic testing.. Cancer Treat Res Commun. 23:100165.
Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, Kolinsky MP et al..  2020.  Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.. N Engl J Med. 382(23):2197-2206.
Sfakianos JP, Daza J, Hu Y, Anastos H, Bryant G, Bareja R, Badani KK, Galsky MD, Elemento O, Faltas BM et al..  2020.  Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers.. Nat Commun. 11(1):2540.
Nauseef JT, Villamar DM, Lebenthal J, Vlachostergios PJ, Tagawa ST.  2020.  An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer.. Expert Opin Pharmacother. 21(8):863-870.
Pisapia DJ, Ohara K, Bareja R, Wilkes DC, Hissong E, Croyle JA, Kim J-H, Saab J, MacDonald TY, Beg S et al..  2020.  Fusions involving BCOR and CREBBP are rare events in infiltrating glioma.. Acta Neuropathol Commun. 8(1):80.
Elemento O.  2020.  The future of precision medicine: towards a more predictive personalized medicine.. Emerg Top Life Sci. 4(2):175-177.
Punjani N, Kang C, Lamb DJ.  2020.  Genetic implications of male-reproductive-health-associated comorbidities.. Turk J Urol.
Trapani D, Curigliano G, Alexandru E, Sternberg CN.  2020.  The global landscape of drug development for kidney cancer.. Cancer Treat Rev. 89:102061.
Davis M, Martini R, Newman L, Elemento O, White J, Verma A, Datta I, Adrianto I, Chen Y, Gardner K et al..  2020.  Identification of Distinct Heterogenic Subtypes and Molecular Signatures Associated with African Ancestry in Triple Negative Breast Cancer Using Quantified Genetic Ancestry Models in Admixed Race Populations.. Cancers (Basel). 12(5)
Claps M, Mennitto A, Guadalupi V, Sepe P, Stellato M, Zattarin E, Gillessen SSilke, Sternberg CN, Berruti A, De Braud FGuglielmo et al..  2020.  Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes.. Cancer Treat Rev. 88:102057.
Yamazaki T, Vanpouille-Box C, Demaria S, Galluzzi L.  2020.  Immunogenic Cell Death Driven by Radiation-Impact on the Tumor Microenvironment.. Cancer Treat Res. 180:281-296.
Galluzzi L, Petroni G, Kroemer G.  2020.  Immunogenicity of cell death driven by immune effectors.. J Immunother Cancer. 8(1)
Rodriguez-Ruiz MEsperanza, Vitale I, Harrington KJ, Melero I, Galluzzi L.  2020.  Immunological impact of cell death signaling driven by radiation on the tumor microenvironment.. Nat Immunol. 21(2):120-134.
Petroni G, Formenti SC, Chen-Kiang S, Galluzzi L.  2020.  Immunomodulation by anticancer cell cycle inhibitors.. Nat Rev Immunol. 20(11):669-679.
Buqué A, Bloy N, Perez-Lanzón M, Iribarren K, Humeau J, Pol JG, Levesque S, Mondragon L, Yamazaki T, Sato A et al..  2020.  Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.. Nat Commun. 11(1):3819.
Galluzzi L, Humeau J, Buqué A, Zitvogel L, Kroemer G.  2020.  Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.. Nat Rev Clin Oncol. 17(12):725-741.
Grunewald CM, Henn A, Galsky MD, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK, Alva AShivaram, Powles T et al..  2020.  Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival.. Urol Oncol. 38(12):934.e1-934.e9.
Xue Y, Liu X, Koundal S, Constantinou S, Dai F, Santambrogio L, Lee H, Benveniste H.  2020.  In vivo T1 mapping for quantifying glymphatic system transport and cervical lymph node drainage.. Sci Rep. 10(1):14592.
Liu H, Paddock MN, Wang H, Murphy CJ, Geck RC, Navarro AJ, Wulf GM, Elemento O, Haucke V, Cantley LC et al..  2020.  The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer.. Cancer Discov. 10(8):1226-1239.
Liu D, Shoag JE, Poliak D, Goueli RS, Ravikumar V, Redmond D, Vosoughi A, Fontugne J, Pan H, Lee D et al..  2020.  Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes.. Nat Commun. 11(1):1987.
Han T, Goswami S, Hu Y, Tang F, Zafra MPaz, Murphy C, Cao Z, Poirier JT, Khurana E, Elemento O et al..  2020.  Lineage Reversion Drives WNT Independence in Intestinal Cancer.. Cancer Discov. 10(10):1590-1609.
Rendeiro AF, Casano J, Vorkas CKyriakos, Singh H, Morales A, DeSimone RA, Ellsworth GB, Soave R, Kapadia SN, Saito K et al..  2020.  Longitudinal immune profiling of mild and severe COVID-19 reveals innate and adaptive immune dysfunction and provides an early prediction tool for clinical progression.. medRxiv.
Xu D, Gokcumen O, Khurana E.  2020.  Loss-of-function tolerance of enhancers in the human genome.. PLoS Genet. 16(4):e1008663.